About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

FIRMAGON® Intensive Drug Monitoring

NCT05181800·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Ferring Pharmaceuticals

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Diagnosed with prostate cancer and in need of ADT
Decision made to prescribe FIRMAGON® prior to enrollment
Willingness and ability to provide written informed consent
The participants are taking the marketed drug FIRMAGON®

You may not be if

Not signed informed consent
Any participants who are unsuitable to participate in this study because of any other reasons will not be qualified to participate in this study.

The record

StatusCompleted

PhaseNo phase

Taking part1,454

StartedAug 2019

UpdatedSep 27, 2024

Conditions

Prostate Cancer

Where1

China Primary Healthcare Foundation
Beijing, China

Clareo Health | FIRMAGON® Intensive Drug Monitoring